S&P 500   3,912.37 (+2.66%)
DOW   31,652.85 (+2.33%)
QQQ   322.88 (+2.78%)
AAPL   126.94 (+4.68%)
MSFT   236.79 (+1.90%)
FB   263.70 (+2.36%)
GOOGL   2,070.33 (+2.39%)
TSLA   709.07 (+4.97%)
AMZN   3,135.66 (+1.38%)
NVDA   548.45 (-0.02%)
BABA   241.93 (+1.75%)
CGC   34.70 (+5.95%)
GE   13.25 (+5.66%)
MU   94.32 (+3.05%)
NIO   49.87 (+8.93%)
AMD   86.18 (+1.98%)
T   28.25 (+1.29%)
F   12.00 (+2.56%)
ACB   11.16 (+6.08%)
DIS   195.27 (+3.30%)
BA   224.63 (+5.95%)
NFLX   548.10 (+1.72%)
BAC   35.97 (+3.63%)
S&P 500   3,912.37 (+2.66%)
DOW   31,652.85 (+2.33%)
QQQ   322.88 (+2.78%)
AAPL   126.94 (+4.68%)
MSFT   236.79 (+1.90%)
FB   263.70 (+2.36%)
GOOGL   2,070.33 (+2.39%)
TSLA   709.07 (+4.97%)
AMZN   3,135.66 (+1.38%)
NVDA   548.45 (-0.02%)
BABA   241.93 (+1.75%)
CGC   34.70 (+5.95%)
GE   13.25 (+5.66%)
MU   94.32 (+3.05%)
NIO   49.87 (+8.93%)
AMD   86.18 (+1.98%)
T   28.25 (+1.29%)
F   12.00 (+2.56%)
ACB   11.16 (+6.08%)
DIS   195.27 (+3.30%)
BA   224.63 (+5.95%)
NFLX   548.10 (+1.72%)
BAC   35.97 (+3.63%)
S&P 500   3,912.37 (+2.66%)
DOW   31,652.85 (+2.33%)
QQQ   322.88 (+2.78%)
AAPL   126.94 (+4.68%)
MSFT   236.79 (+1.90%)
FB   263.70 (+2.36%)
GOOGL   2,070.33 (+2.39%)
TSLA   709.07 (+4.97%)
AMZN   3,135.66 (+1.38%)
NVDA   548.45 (-0.02%)
BABA   241.93 (+1.75%)
CGC   34.70 (+5.95%)
GE   13.25 (+5.66%)
MU   94.32 (+3.05%)
NIO   49.87 (+8.93%)
AMD   86.18 (+1.98%)
T   28.25 (+1.29%)
F   12.00 (+2.56%)
ACB   11.16 (+6.08%)
DIS   195.27 (+3.30%)
BA   224.63 (+5.95%)
NFLX   548.10 (+1.72%)
BAC   35.97 (+3.63%)
S&P 500   3,912.37 (+2.66%)
DOW   31,652.85 (+2.33%)
QQQ   322.88 (+2.78%)
AAPL   126.94 (+4.68%)
MSFT   236.79 (+1.90%)
FB   263.70 (+2.36%)
GOOGL   2,070.33 (+2.39%)
TSLA   709.07 (+4.97%)
AMZN   3,135.66 (+1.38%)
NVDA   548.45 (-0.02%)
BABA   241.93 (+1.75%)
CGC   34.70 (+5.95%)
GE   13.25 (+5.66%)
MU   94.32 (+3.05%)
NIO   49.87 (+8.93%)
AMD   86.18 (+1.98%)
T   28.25 (+1.29%)
F   12.00 (+2.56%)
ACB   11.16 (+6.08%)
DIS   195.27 (+3.30%)
BA   224.63 (+5.95%)
NFLX   548.10 (+1.72%)
BAC   35.97 (+3.63%)
Log in
OTCMKTS:PXSLY

Pharmaxis Stock Forecast, Price & News

$1.01
+0.07 (+7.56 %)
(As of 02/26/2021 10:07 PM ET)
Add
Compare
Today's Range
$1.01
Now: $1.01
$1.01
50-Day Range
$0.94
MA: $1.10
$1.16
52-Week Range
$0.56
Now: $1.01
$1.16
Volume3,000 shs
Average Volume1,683 shs
Market Capitalization$26.60 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PXSLY
CUSIPN/A
Phone61-2-9454-7200
Employees64
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.75 million
Book Value$0.04 per share

Profitability

Miscellaneous

Market Cap$26.60 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.58 out of 5 stars

Medical Sector

1367th out of 1,965 stocks

Pharmaceutical Preparations Industry

608th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$1.01
+0.07 (+7.56 %)
(As of 02/26/2021 10:07 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PXSLY News and Ratings via Email

Sign-up to receive the latest news and ratings for PXSLY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pharmaxis (OTCMKTS:PXSLY) Frequently Asked Questions

What stocks does MarketBeat like better than Pharmaxis?

Wall Street analysts have given Pharmaxis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pharmaxis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pharmaxis?

Pharmaxis saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 6,000 shares, an increase of 5,900.0% from the January 28th total of 100 shares. Based on an average daily trading volume, of 1,200 shares, the short-interest ratio is presently 5.0 days.
View Pharmaxis' Short Interest
.

How has Pharmaxis' stock been impacted by COVID-19?

Pharmaxis' stock was trading at $1.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PXSLY shares have decreased by 35.3% and is now trading at $1.01.
View which stocks have been most impacted by COVID-19
.

Who are Pharmaxis' key executives?

Pharmaxis' management team includes the following people:
  • Mr. Gary Jonathan Phillips, CEO, MD & Director (Age 60)
  • Mr. David Morris McGarvey BA, CA, CPA, CFO & Company Sec. (Age 65)
  • Dr. Wolfgang G. Jarolimek Ph.D., B.Sc. Ph.D., Head of Drug Discovery (Age 57)
  • Ms. Kristen Morgan B.Sc., BSc, PGDipBusAdmin, MMedSc, Alliance Management - Head of Medical & Regulatory Affairs (Age 49)
  • Dr. Brett Charlton Ph.D., MBBS Ph.D., Medical Director (Age 65)
  • Mr. Cameron David Billingsley, Gen. Counsel (Age 44)
  • Dr. Dieter Hamprecht, Head of Chemistry for Drug Discovery

Who are some of Pharmaxis' key competitors?

What is Pharmaxis' stock symbol?

Pharmaxis trades on the OTCMKTS under the ticker symbol "PXSLY."

How do I buy shares of Pharmaxis?

Shares of PXSLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharmaxis' stock price today?

One share of PXSLY stock can currently be purchased for approximately $1.01.

How much money does Pharmaxis make?

Pharmaxis has a market capitalization of $26.60 million and generates $8.75 million in revenue each year.

How many employees does Pharmaxis have?

Pharmaxis employs 64 workers across the globe.

What is Pharmaxis' official website?

The official website for Pharmaxis is www.pharmaxis.com.au.

Where are Pharmaxis' headquarters?

Pharmaxis is headquartered at 20 RODBOROUGH ROAD, FRENCHS FOREST C3, 2086.

How can I contact Pharmaxis?

Pharmaxis' mailing address is 20 RODBOROUGH ROAD, FRENCHS FOREST C3, 2086. The company can be reached via phone at 61-2-9454-7200 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.